Aadi Bioscience, Inc.

NasdaqCM:AADI Voorraadrapport

Marktkapitalisatie: US$56.7m

Aadi Bioscience Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Aadi Bioscience de winst en omzet met respectievelijk 56.1% en 38.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 55.9% per jaar.

Belangrijke informatie

56.1%

Groei van de winst

55.9%

Groei van de winst per aandeel

Biotechs winstgroei28.4%
Inkomstengroei38.8%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt07 Nov 2024

Recente toekomstige groei-updates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Winst- en omzetgroeiprognoses

NasdaqCM:AADI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202643-26-52N/A3
12/31/202528-29-56N/A4
12/31/202426-52-49N/A2
9/30/202425-62-56-54N/A
6/30/202424-65-54-50N/A
3/31/202424-69-61-58N/A
12/31/202324-66-64-60N/A
9/30/202323-63-65-61N/A
6/30/202322-62-60-58N/A
3/31/202319-62-53-52N/A
12/31/202215-61-50-50N/A
9/30/202211-63-51-51N/A
6/30/20227-136-60-60N/A
3/31/20223-119-52-52N/A
12/31/20211-111-22-22N/A
9/30/202114-87-13-13N/A
6/30/202115-211N/A
3/31/202115-622N/A
12/31/202015-4-13-13N/A
12/31/20191-13-8-8N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat AADI de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat AADI de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat AADI de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van AADI ( 38.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van AADI ( 38.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van AADI naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven